The threshold between preclinical AD and the onset of cognitive symptoms is marked by the increasing burden of NFT pathology, and the accumulation of aggregated p-tau appears to be the primary mediator of cognitive dysfunction (5). The gene discussed is MAPT; the disease is Alzheimer disease.